Skip to main content

Paolo Mannelli

Professor of Psychiatry and Behavioral Sciences
Psychiatry & Behavioral Sciences, Adult Psychiatry & Psychology
Box 3074 Med Ctr, Durham, NC 27710
2213 Elba Street, Suite 156, Durham, NC 27705

Selected Grants


Neurobehavioral mechanisms linking childhood adversity to increased risk for smoking

ResearchPhysician · Awarded by National Institutes of Health · 2022 - 2027

Impact of new standards for tobacco products among dual e-cigarette/combusted cigarette users

ResearchPhysician · Awarded by National Institutes of Health · 2019 - 2025

Randomized Controlled Trial of a Novel Smoking Cessation Application Tailored to Individuals with Serious Mental Illness

ResearchPrincipal Investigator · Awarded by Wake Forest University Health Sciences · 2024 - 2024

Using Very Low Nicotine Content Cigarettes as a Strategy to Disrupt the Pain-Smoking Reinforcement Cycle

ResearchPhysician · Awarded by National Institutes of Health · 2021 - 2024

Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace

ResearchPhysician · Awarded by University of Minnesota · 2018 - 2024

The impact of chronic pain on buprenorphine treatment utilization and retention among patients with opioid use disorder.

ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2023

Mid Southern Primary Care Networks Node

ResearchInvestigator · Awarded by National Institutes of Health · 2015 - 2023

Early-phase Studies of a Tailored Evidence-Based Smoking Cessation mHealth App for Persons Living with HIV

ResearchPhysician · Awarded by National Institutes of Health · 2019 - 2022

Substance Abuse/Treatment Gaps in Asians, Pacific Islanders & Multiple-race Individuals

ResearchCo Investigator · Awarded by National Institutes of Health · 2013 - 2021

Alkermes ALK6428-A302

Clinical TrialPrincipal Investigator · Awarded by Alkermes, plc · 2017 - 2020

Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers

ResearchPhysician · Awarded by National Institutes of Health · 2016 - 2020

Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers

ResearchPhysician · Awarded by National Institutes of Health · 2015 - 2019

RCT of an Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Abuse

ResearchInvestigator · Awarded by National Institutes of Health · 2013 - 2019

Retrospective Evaluation of Zubsolv Outcomes - A Longitudinal View (REZOLV)

ResearchPrincipal Investigator · Awarded by OREXO · 2015 - 2018

Carolinas Comprehensive Substance Abuse Services Project

ResearchPhysician · Awarded by Substance Abuse and Mental Health Services Administration · 2012 - 2018

Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace

ResearchMedical Director · Awarded by University of Minnesota · 2017 - 2017

Project 2: Evaluating New Nicotine Standards for Cigarettes - Supplement

ResearchPhysician · Awarded by University of Minnesota · 2014 - 2017

Southern Consortium Node of the Clinical Trials Network

ResearchClinical Investigator · Awarded by Medical University of South Carolina · 2013 - 2015

Carolina Alcohol and Drug Expansion Team (CADET)

ResearchPsychologist · Awarded by Department of Health and Human Services · 2007 - 2013

8/1/200Epidemiology of Non-Medical Prescription Analgesic Use

ResearchCo Investigator · Awarded by National Institutes of Health · 2007 - 2012

Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Use/Abuse

ResearchPhysician · Awarded by National Institutes of Health · 2008 - 2011

Place of Low-Dose Naltrexone in Opiate Detoxification

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2004 - 2006

Serotonin and Cocaine Dependence

ResearchCo Investigator · Awarded by National Institutes of Health · 2003 - 2006

External Relationships


  • Citeline and Norstella
  • Guidepoint Global
  • MEDACorp (Leerink Swann & Co)
  • Medical Leverage
  • Pharmapointe Inc
  • clinilabs drug development corporation

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.